Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial
Luís Puig, Andrey L Bakulev, Muza M Kokhan, Alexey V Samtsov, Vladislav R Khairutdinov, Maria A Morozova, Nikita A Zolkin, Ivan V Kuryshev, Alexey N Petrov, Antonina V Artemeva, Arina V Zinkina-Orikhan, Luís Puig, Andrey L Bakulev, Muza M Kokhan, Alexey V Samtsov, Vladislav R Khairutdinov, Maria A Morozova, Nikita A Zolkin, Ivan V Kuryshev, Alexey N Petrov, Antonina V Artemeva, Arina V Zinkina-Orikhan
Abstract
Introduction: Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate-to-severe plaque psoriasis in a phase 2 clinical study. Herein we report the results of 54 weeks of a phase 3 PLANETA trial aimed to evaluate the efficacy and safety of two NTK regimens vs. placebo.
Methods: Two hundred thirteen patients with moderate-to-severe plaque psoriasis were randomly assigned to receive NTK 120 mg once every 2 weeks (NTK Q2W), NTK 120 mg once every 4 weeks (NTK Q4W) or placebo. During the first 3 weeks, patients received subcutaneous injections of NTK or placebo (according to the allocation) once a week. Patients in the NTK Q2W group then received NTK at weeks 4, 6, 8 and 10. Subjects in the NTK Q4W group received NTK at weeks 6 and 10 and placebo at weeks 4 and 8. Patients in the placebo group received placebo injections at weeks 4, 6, 8 and 10. Treatment was unblinded at week 12. During the open-label phase, patients in both NTK groups continued to receive NTK Q4W. The primary efficacy endpoint was the proportion of patients in each group who achieved a ≥ 75% reduction from baseline in psoriasis area and severity index (PASI 75) at week 12.
Results: A total of 77.7%, 83.3% and 0% of patients had a PASI 75 response at week 12 in the NTK Q2W, NTK Q4W and placebo groups, respectively (P < 0.0001, Fisher's exact test, ITT). The effect was maintained throughout the 1-year treatment. NTK showed a good safety profile and low immunogenicity.
Conclusion: Treatment with NTK results in high rates of sustained clinical response in patients with moderate-to-severe plaque psoriasis. The study is ongoing; thus, long-term use efficacy and safety data are forthcoming.
Clinical trial registration: The trial is registered at the US National Institutes of Health (ClinicalTrials.gov; NCT03390101).
Keywords: Interleukin-17 inhibitors; Netakimab; Psoriasis.
© 2021. The Author(s).
Figures
References
- Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2012;122(11):487–511. doi: 10.1042/CS20110496.
- Erdes S, Nasonov E, Kunder E, et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol. 2020;38(1):27–34.
- Bakulev AL, Samtsov AV, Kubanov AA, Khairutdinov VR, Kokhan MM, Artemyeva AV, Derbin SI, Chernyaeva EV, Ivanov RA. Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085–2-ext. Vestnik dermatologii i venerologii. 2019;95(3):54–64. doi: 10.25208/0042-4609-2019-95-3-54-64.
- Common Terminology Criteria for Adverse Events (CTCAE). . Accessed 13 Jan 2021.
- Farahnik B, Beroukhim K, Zhu TH, et al. Ixekizumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb) 2016;6(1):25–37. doi: 10.1007/s13555-016-0102-0.
- European medical Agency. Assessment Report EMA/CHMP/389874/2014. . Accessed 25 Jan 2021.
- Gordon K, Blauvelt A, Papp K, et al. Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345–356. doi: 10.1056/NEJMoa1512711.
- Spuls P, Witkamp L, Bossuyt PM, Bos JD. The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies. Arch Dermatol. 2004;140(3):338–344. doi: 10.1001/archderm.140.3.338.
Source: PubMed